Company Profile for MiddleBrook Pharmaceuticals, Inc.
13 Mars 2009 - 3:40PM
Business Wire
MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) is a
pharmaceutical company focused on developing and commercializing
anti-infective products that fulfill unmet medical needs. We have
developed a proprietary delivery technology called PULSYS�, which
enables the pulsatile delivery, or delivery in rapid bursts, of
certain drugs. We are currently developing a portfolio of
anti-infective PULSYS products. Our near-term corporate strategy is
to improve dosing regimens and/or reduce frequency of dosing which
we believe will result in improved patient dosing convenience and
compliance for antibiotics that have been used and trusted by
physicians and patients for decades. MiddleBrook currently markets
KEFLEX, the immediate-release brand of cephalexin, and MOXATAG �
the first and only FDA-approved once-daily amoxicillin. For more
information about MiddleBrook, please visit
www.middlebrookpharma.com.
Company:
� MiddleBrook Pharmaceuticals, Inc. �
Headquarters Address:
7 Village Circle Suite 100 Westlake, TX 76262 �
Main Telephone:
817-837-1200 �
Website:
www.middlebrookpharma.com
�
Ticker/ISIN:
MBRK(NASDAQ)/US5960871060 �
Type of Organization:
Public � Industry: Pharmaceutical �
Key Executives:
CEO: John Thievon
CFO: David Becker
�
Investor Relations
Contact:
Faith Pomeroy-Ward
Phone:
817-837-1208
Email:
faith@middlebrookpharma.com
Middlebrook Pharmaceuticals (MM) (NASDAQ:MBRK)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Middlebrook Pharmaceuticals (MM) (NASDAQ:MBRK)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about Middlebrook Pharmaceuticals (MM) (NASDAQ): 0 recent articles
Plus d'articles sur MiddleBrook Pharmaceuticals, Inc.